Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00174512 |
To assess the effects of GTN on QT and QTc in subjects with And without atrial pacing. This will be done with and without autonomic blockade at two different pacing rates. Moxifloxacin effect on QT and QTc will also be assessed in atrially paced patients at two different pacing rates with and without autonomic blockade
Condition | Intervention | Phase |
---|---|---|
Patients With Pace Makers But no Evidence of Ischemic Heart Disease |
Drug: GTN Drug: Moxifloxacin |
Phase I |
Study Type: | Interventional |
Study Design: | Educational/Counseling/Training, Randomized, Open Label, Active Control, Crossover Assignment, Pharmacodynamics Study |
Official Title: | A Methodological Open-Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarisation and QT Interval At Fixed Heart Rate Under Autonomic Blockade |
Estimated Enrollment: | 36 |
Study Start Date: | March 2005 |
Estimated Study Completion Date: | June 2006 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Belgium | |
Pfizer Investigational Site | |
Bruxelles (Brussels), Belgium | |
United Kingdom | |
Pfizer Investigational Site | |
London, United Kingdom | |
Pfizer Investigational Site | |
Manchester, United Kingdom | |
Pfizer Investigational Site | |
Liverpool, United Kingdom | |
Pfizer Investigational Site | |
Leicester, United Kingdom | |
United Kingdom, Scotland | |
Pfizer Investigational Site | |
Glasgow, Scotland, United Kingdom |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A9001226 |
Study First Received: | September 12, 2005 |
Last Updated: | November 7, 2006 |
ClinicalTrials.gov Identifier: | NCT00174512 History of Changes |
Health Authority: | United Kingdom: Research Ethics Committee |
Nitroglycerin Anti-Infective Agents Heart Diseases Moxifloxacin |
Myocardial Ischemia Vascular Diseases Ischemia |
Anti-Infective Agents Heart Diseases Moxifloxacin Therapeutic Uses |
Myocardial Ischemia Vascular Diseases Cardiovascular Diseases Pharmacologic Actions |